-- Sino Biopharmaceutical (HKG:1177) enrolled the first patient in the phase 3 clinical trial of cafelkibart to treat gastric cancer, the firm said in a Hong Kong bourse filing Thursday.
The company will study the medicine's effectiveness in treating gastric cancer or gastroesophageal junction adenocarcinoma as a second-line treatment.
Cafelkibart is also known as LM-108 and was developed by the company's LaNova Medicines unit.
China Hainan Rubber Industry (SHA:601118) received 74.8 million yuan in insurance compensation for cold damage that affected its rubber trees in January, according to a Thursday filing with the Shanghai bourse.The payout includes 66.7 million yuan under the full cost insurance policy that will reduce agricultural production costs and 8.1 million yuan under the materialized cost insurance policy that will reduce productive biological assets.The final accounting treatment will depend on audit confirmation.Shares of the rubber company were down 1% in recent trade.
UnUsUaL (SGX:1D1) is expecting to book a net loss for the fiscal year ended March 31, according to a filing with the Singapore Exchange on Wednesday.Shares of the live events and concerts company plunged over 7% in Thursday trading.The company has attributed its net loss to increased operational costs amid heightened market competition and will release its results on May 28.
BlueNord (BNOR.OL) said Wednesday it issued a new senior unsecured bond worth $400 million with a fixed interest rate of 7.875% per annum.The five-year bond is due in 2031, with the net proceeds earmarked for refinancing the oil and gas company's $300 million senior unsecured bonds, as well as for general corporate purposes. Settlement is scheduled for May 19.DNB Carnegie, Fearnley Securities, and Pareto Securities acted as joint bookrunners for the bond issue.